


CLAIMS

1. A compound represented by general formula (I):


[Chemical Formula 1]



wherein

R¹ represents

[Chemical Formula 2],



* represents a binding site with a nitrogen atom, and

R² represents a methyl group or an ethyl group;

or a pharmaceutically acceptable salt thereof.

2. A compound selected from the group consisting of the following compounds:

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-((3S,4R)-4-hydroxytetrahydrofuran-3-yl)benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-((3R,4S)-4-

hydroxytetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl)-
1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R,4S)-4-
hydroxytetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl)-
1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4R)-4-
hydroxytetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-
1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R)-2-
oxotetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-
1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S)-2-
oxotetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-
1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S)-5-
oxotetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-
1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R)-2-oxopyrrolidin-3-
yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-
1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S)-2-oxopyrrolidin-3-
yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-
1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4S)-4-hydroxy-2-
oxotetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl)-
1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R)-2-oxopyrrolidin-3-

yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S)-2-oxopyrrolidin-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4R)-4-hydroxy-2-oxotetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R,4R)-4-hydroxytetrahydrofuran-3-yl]benzamide; and

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4S)-4-hydroxytetrahydrofuran-3-yl]benzamide;

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising, as an active ingredient, a compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition according to claim 3, for treating type 1 diabetes, type 2 diabetes, or obesity.

5. A pharmaceutical composition according to claim 3, for protecting β cells or the pancreas.

6. Use of a compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, for preparing a

pharmaceutical composition.


7. A method for treating a disease, the method comprising administering to a mammal a compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof.

8. A method according to claim 7, wherein the mammal is a human being.

CLAIMS

1. A compound represented by general formula (I):



[Chemical Formula 1]



wherein

R¹ represents

[Chemical Formula 2],



* represents a binding site with a nitrogen atom, and

R² represents a methyl group or an ethyl group;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 selected from the group consisting of the following compounds:

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4R)-4-hydroxytetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R,4S)-4-hydroxytetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R,4S)-4-hydroxytetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4R)-4-hydroxytetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R)-2-oxotetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S)-2-oxotetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S)-5-oxotetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R)-2-oxopyrrolidin-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S)-2-oxopyrrolidin-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4S)-4-hydroxy-2-oxotetrahydrofuran-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R)-2-oxopyrrolidin-3-yl]benzamide;

4-(5-((1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl)-

1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S)-2-oxopyrrolidin-3-yl]benzamide;

4-(5-[(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl]-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4R)-4-hydroxy-2-oxotetrahydrofuran-3-yl]benzamide;

4-(5-[(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl]-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R,4R)-4-hydroxytetrahydrofuran-3-yl]benzamide; and

4-(5-[(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl]-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4S)-4-hydroxytetrahydrofuran-3-yl]benzamide;
or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising, as an active ingredient, a compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition according to claim 3, for use in treating type 1 diabetes, type 2 diabetes, or obesity.

5. A pharmaceutical composition according to claim 3, for use in protecting β cells or the pancreas.

6. A compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof for use in the treatment of type 1 diabetes, type 2 diabetes or obesity.

7. A compound according to claim 1 or 2 or a

pharmaceutically acceptable salt thereof for use in protecting β cells or the pancreas.